A Phase 4 interventional study of Ketamine Hydrochloride in Major Depressive Disorder, sponsored by Ehave Inc.. Status unknown. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-08-22.
Sponsored by Ehave Inc. · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies testing ketamine in Depressive Disorder, Major — 21 open to participants now, 26 under way, 5 of them phase 3. Ketamine · Depressive Disorder, Major.
Among the 89 studies testing ketamine in Depressive Disorder, Major, this one is the 48th largest by planned enrollment, is the only one that started in 2023, is one of 16 in phase 4, and was the 71st registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →21 of the 89 studies testing ketamine in Depressive Disorder, Major are open now, in 9 countries. Recruiting first, the newest first:
Joshua Rosenblat · Sites in Canada
Ages 18–70
University of Pennsylvania · Sites in United States
Ages 25–65
Università Vita-Salute San Raffaele · Sites in Italy
Ages 18–70
The Royal's Institute of Mental Health Research · Sites in Canada
Ages 18–65
Mayo Clinic · Sites in United States
Ages 18–65
By country, each count listing its studies:
Ketamine: first FDA approval 1970 (KETALAR). What it is approved for, and how studies give it, is on its page →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 32 · Phase 3 13 · Phase 4 16
First in 2004; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 35 is below the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 38 across the 89 interventional studies. Of the 48 that completed or were terminated, 29 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 89 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Ehave Inc. as lead sponsor.
Ehave Inc. has 1 study filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
11 of the studies testing ketamine in Depressive Disorder, Major that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06891300Phase 3The Royal's Institute of Mental Health ResearchUnderstanding and Treating Suicidal Ideation With Ketamine | 2027-03 |
| NCT03573349Mayo ClinicKetamine Associated ACC GABA and Glutamate Change and Depression Remission: | 2026-12 |
| NCT06228391Minneapolis Veterans Affairs Medical CenterKetamine Treatment for PTSD and MDD in TBI | 2026-12 |
| NCT06788249University of PennsylvaniaPilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine | 2026-12-15 |
| NCT06480201Texas A&M UniversityGamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 89 studies testing ketamine in Depressive Disorder, Major, from their registry updates:
This tab as a report to print or save as PDF → With an account.
There are many common pharmacological treatments for major depression disorder (MDD), however the efficacy of these drugs often fails in severe cases. Intravenous (IV) administered ketamine may offer the potential for remission of the symptoms in patients with MDD; however it has not yet been approved by FDA for this purpose. This study will make use of an electroencephalography (EEG) machine to measure the brain's activity and response while the IV ketamine is being delivered. The objective of this study is to characterize the change in EEG response of patients with MDD, during and 4 weeks after a course of IV ketamine infusions.
This study will enroll 35 patients with major depressive disorder. Candidates for participation in the study will typically be either referred to the clinic through their healthcare provider or will have sought out participation on their own accord based on advertising. Subjects will be screened for eligibility and suitable patients will be invited to attend a screening visit in the clinic and complete informed consent.
Upon determining eligibility, subjects will have their first treatment session booked within 42 days of screening (Baseline, visit 0). Three subsequent weekly (±3 days) ketamine therapy treatment sessions will occur on days 7, 14 and 21, for a total of four ketamine infusions over four weeks. All patients will return for a follow-up visit at 4-weeks post final treatment visit, day 49.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
50-60 minutes intravenous infusion of 60mg ketamine
Drug: Ketamine Hydrochloride
Patients with a diagnosis of Major Depressive Disorder (MDD) will be enrolled to receive four 50-60 minute infusions of 60mg ketamine hydrochloride
Also known as: NDC 67457-108-00
Characterizing the changes in EEG reading frequencies from pre- IV ketamine infusion treatment (baseline).
Alpha, Beta, Delta, Theta and Gamma frequencies will be examined with portable NeuroEEG™, a 19 channels and 22 electrodes cap based on 10-20 distribution
Time frame: 30-minute pre-treatment baseline and throughout infusion (approximately 50-60 minutes)
Characterizing the changes in EEG reading waveforms from pre- IV ketamine infusion treatment (baseline).
Alpha, Beta, Delta, Theta and Gamma waveforms will be examined with portable NeuroEEG™, a 19 channels and 22 electrodes cap based on 10-20 distribution
Time frame: 30-minute pre-treatment baseline and throughout infusion (approximately 50-60 minutes)
Characterizing the changes in EEG reading amplitudes from pre- IV ketamine infusion treatment (baseline).
Alpha, Beta, Delta, Theta and Gamma amplitude will be examined with portable NeuroEEG™, a 19 channels and 22 electrodes cap based on 10-20 distribution
Time frame: 30-minute pre-treatment baseline and throughout infusion (approximately 50-60 minutes)
Characterizing the changes in EEG reading patterns from pre- IV ketamine infusion treatment (baseline).
Alpha, Beta, Delta, Theta and Gamma reading patterns will be examined with portable NeuroEEG™, a 19 channels and 22 electrodes cap based on 10-20 distribution
Time frame: 30-minute pre-treatment baseline and throughout infusion (approximately 50-60 minutes)
Characterizing the changes in EEG reading frequencies from pre- IV ketamine infusion treatment (baseline) and 4 weeks post-treatment course
Alpha, Beta, Delta, Theta and Gamma frequencies will be examined with portable NeuroEEG™, a 19 channels and 22 electrodes cap based on 10-20 distribution
Time frame: Pre-treatment baseline, 4 weeks post-treatment course
Characterizing the changes in EEG reading waveforms from pre- IV ketamine infusion treatment (baseline) and 4 weeks post-treatment course
Alpha, Beta, Delta, Theta and Gamma waveforms will be examined with portable NeuroEEG™, a 19 channels and 22 electrodes cap based on 10-20 distribution
Time frame: Pre-treatment baseline, 4 weeks post-treatment course
Characterizing the changes in EEG reading amplitudes from pre- IV ketamine infusion treatment (baseline) and 4 weeks post-treatment course
Alpha, Beta, Delta, Theta and Gamma amplitude will be examined with portable NeuroEEG™, a 19 channels and 22 electrodes cap based on 10-20 distribution
Time frame: Pre-treatment baseline, 4 weeks post-treatment course
Characterizing the changes in EEG reading patterns from pre- IV ketamine infusion treatment (baseline) and 4 weeks post-treatment course
Alpha, Beta, Delta, Theta and Gamma amplitude will be examined with portable NeuroEEG™, a 19 channels and 22 electrodes cap based on 10-20 distribution
Time frame: Pre-treatment baseline, 4 weeks post-treatment course
Incidence of medically significant changes in blood pressure during ketamine infusion
Time frame: Pre-treatment baseline; treatment initiation, 0 minutes; 20 minutes, 40 minutes; 60 minutes post-infusion
Incidence of medically significant changes in Oxygen Saturation (SpO2) during ketamine infusion
Time frame: Pre-treatment baseline; treatment initiation, 0 minutes; 20 minutes, 40 minutes; 60 minutes post-infusion
Incidence of medically significant changes in heart rate during ketamine infusion
Time frame: Pre-treatment baseline; treatment initiation, 0 minutes; 20 minutes, 40 minutes; 60 minutes post-infusion
Incidence of medically significant changes in respiratory rate during ketamine infusion
Time frame: Pre-treatment baseline; treatment initiation, 0 minutes; 20 minutes, 40 minutes; 60 minutes post-infusion
Changes from baseline in the Dissociative Experiences Scale (DES) Total Score
The Dissociative Experiences Scale (DES) is a 28-item scale assessing the subject's experiences in his/her daily life. The subject determines to what degree he/she has been facing the situation by selecting a percentage from 0% (never) to 100% (always), with 10% increments in between. Higher scores mean higher severity
Time frame: Baseline (Day 0), follow-up visit (Day 42)
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2023; primary completion for Jan 2024, 12 months later.
Of 98 phase 4 interventional studies under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 58. This study's planned 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ketamine